SpaMedica treats cataracts and AMD across Cheshire and Merseyside
- NHS Cheshire and Merseyside ICB
- North West
- 1 bid
SpaMedica treats cataracts, age-related macular degeneration (AMD) and posterior capsule opacification for NHS Cheshire and Merseyside ICB. The service is for patients registered with GPs across Cheshire and Merseyside and works on a patient choice model.
Patient choice carried 99% of the weighting in the award and price 1%. The one-year contract is worth £15.8m and is due to run to March 2027.
- What
- Cataract and ophthalmology services
- Supplier
- SpaMedica
- Value
- £15.8m
- How it was bought
- Not published
- 1 bid
- Dates and next
- 18 Nov 2025